Search research articles
Contact Us
Filters
Showing results (241-250 of 287) with videos related to
Page
of 29
Sort By:
European Journal of Cancer & Clinical Oncology
|
January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study
E Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer
|
May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma
S Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
P A Palmer, J Vinke, P Evers, et al.
Cancer Research
|
May 1, 1991
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2
F Velotti, A Stoppacciaro, L Ruco, et al.
Immunology Letters
|
July 1, 1992
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response
R Isacson, E Kedar, V Barak, et al.
Nouvelle Revue Francaise D'Hematologie
|
January 1, 1989
Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK)
C Coze, V Combaret, I Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1993
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
D Khayat, C Borel, J M Tourani, et al.
Oncogene
|
September 20, 2005
Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas
J V Kichina, M Zeremski, L Aris, et al.
Cancer Treatment Reviews
|
June 1, 1989
A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies
A Lindemann, K Hoeffken, R E Schmidt, et al.
Cancer Treatment Reviews
|
June 1, 1989
Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study
G Stoter, S D Fosså, C Rugarli, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 287) with videos related to
Sort By:
Page
of 29
European Journal of Cancer & Clinical Oncology
|
January 1, 1989
Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study
E Shiloni, P Pouillart, J Janssens, et al.
British Journal of Cancer
|
May 1, 1992
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma
S Négrier, A Mercatello, M Bret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1992
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
P A Palmer, J Vinke, P Evers, et al.
Cancer Research
|
May 1, 1991
Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2
F Velotti, A Stoppacciaro, L Ruco, et al.
Immunology Letters
|
July 1, 1992
Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response
R Isacson, E Kedar, V Barak, et al.
Nouvelle Revue Francaise D'Hematologie
|
January 1, 1989
Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK)
C Coze, V Combaret, I Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1993
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
D Khayat, C Borel, J M Tourani, et al.
Oncogene
|
September 20, 2005
Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas
J V Kichina, M Zeremski, L Aris, et al.
Cancer Treatment Reviews
|
June 1, 1989
A multicenter trial of interleukin-2 and low-dose cyclophosphamide in highly chemotherapy-resistant malignancies
A Lindemann, K Hoeffken, R E Schmidt, et al.
Cancer Treatment Reviews
|
June 1, 1989
Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study
G Stoter, S D Fosså, C Rugarli, et al.
Page
of 29